Eikon Therapeutics, based in Hayward, Calif., was founded in 2019 by Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian. In 2014, Betzig shared the Nobel Prize in Chemistry. Robert Perlmutter is the company’s chairman and CEO. Eikon, which was last valued on January 2022 at $3.1 billion, is a drug discovery and development company that leverages superior engineering and high-performance computing to analyze single molecule protein behavior in living cells.
In January 2022, the company raised $525 million in Series B financing led by more than a dozen investors including T. Rowe Price Associates, Inc., Canada Pension Plan Investment Board, UC Investments, Soros Capital and Schroders Capital.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/16/2023 | Series C | $535MM | $xx.xx | $4.74B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
24,884,830
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Undisclosed Investors
|
||||||
01/06/2022 | Series B | $525MM | $xx.xx | $3.1B | Adia, Ame Cloud Ventures, Canada Pension Plan Investment Board, E15 Vc, Ecor1 Capital, Foresite Capital, General Catalyst, Harel Insurance, Hartford Healthcare Endowment, Horizon Ventures, Inc, Innovaction Endeavors, Lux Capital, Schroders Capital, Soros Capital, Stepstone Group, The Column Group, T. Rowe Price Associates, Uc Investments | |
Price per Share
$xx.xx
Shares Outstanding
29,680,164
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Adia, Ame Cloud Ventures, Canada Pension Plan Investment Board, E15 Vc, Ecor1 Capital, Foresite Capital, General Catalyst, Harel Insurance, Hartford Healthcare Endowment, Horizon Ventures, Inc, Innovaction Endeavors, Lux Capital, Schroders Capital, Soros Capital, Stepstone Group, The Column Group, T. Rowe Price Associates, Uc Investments
|
||||||
05/05/2021 | Series A | $48MM | $xx.xx | $248.17MM | Foresite Capital, Innovation Endeavors, Lux Capital, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
48,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Foresite Capital, Innovation Endeavors, Lux Capital, The Column Group
|
||||||
05/05/2021 | Series A-1 | $102.54MM | $xx.xx | $248.17MM | Foresite Capital, Innovation Endeavors, Lux Capital, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
51,268,891
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Foresite Capital, Innovation Endeavors, Lux Capital, The Column Group
|